View Older Stories
-
RxSight (RXST) Reiterated at Hold by Stifel Amid LAL, LDD Slowdown
-
RxSight Inc. (RXST) PT Raised to $10 at Stifel
-
RxSight Inc. (RXST) PT Raised to $12 at Needham
-
RxSight, Inc. (RXST) Tops Q3 EPS by 34c, provides guidance
-
RXST STOCK LOSS: RxSight, Inc. Investors with Losses are Notified of Tomorrow's September 22 Deadline in Securities Fraud Class Action
-
RxSight Inc. (RXST) PT Lowered to $8 at UBS
-
RxSight, Inc. (RXST) Misses Q2 EPS by 10c, provides guidance
-
Important Notice to Long-term Shareholders of RxSight, Inc. (RXST): Grabar Law Office Investigates Claims on Your Behalf
-
RXST LOSS NOTICE: BFA Law Reminds RxSight, Inc. Investors of the Pending Securities Fraud Investigation
-
RXST SECURITIES NOTICE: RxSight, Inc. Investors with Losses are Reminded to Contact BFA Law about the Continuing Securities Fraud Investigation
-
RXST INVESTIGATION ALERT: BFA Law Alerts RxSight, Inc. Investors to Contact the Firm about its Ongoing Securities Fraud Investigation
-
Morgan Stanley Downgrades RxSight Inc. (RXST) to Equalweight
-
Jefferies Downgrades RxSight Inc. (RXST) to Hold
-
RxSight (RXST) call put ratio 2.7 calls to 1 put as share price down 38%
-
Needham Reiterates Buy Rating on RxSight Inc. (RXST)
-
BTIG Downgrades RxSight Inc. (RXST) to Neutral
-
Wells Fargo Downgrades RxSight Inc. (RXST) to Equal Weight
-
After-hours movers: Mobileye, RxSight, Cogent Biosciences
-
RxSight cuts 2025 revenue guidance as lens device sales decline
-
Stifel Reiterates Hold Rating on RxSight Inc. (RXST)
-
Piper Sandler Highlights Top Medtech Picks and Catalyst-Rich Names
-
RxSight (RXST) option IV flat as share price up 13%
-
Wells Fargo Upgrades RxSight Inc. (RXST) to Overweight, 'Too Cheap Given Market Opportunity & First Mover Advantage'
-
RxSight, Inc. (RXST) Tops Q1 EPS by 17c
-
Piper Sandler Starts RxSight Inc. (RXST) at Neutral
-
UBS Downgrades RxSight Inc. (RXST) to Neutral
-
RxSight (RXST) call put ratio 1 call to 40 puts with a focus on September 15 puts
-
JPMorgan Double Downgrades RxSight Inc. (RXST) to Underweight
-
RxSight (RXST) Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance (Earlier)
-
RxSight Inc. (RXST) PT Lowered to $28 at BTIG
-
Stifel Reiterates Hold Rating on RxSight Inc. (RXST)
-
BofA Securities Downgrades RxSight Inc. (RXST) to Underperform
-
Needham Reiterates Buy Rating on RxSight Inc. (RXST)
-
RxSight Inc. (RXST) PT Lowered to $36 at BofA Securities
-
RxSight Inc. (RXST) PT Lowered to $28 at Stifel
-
RxSight Inc. (RXST) PT Lowered to $50 at Jefferies
-
RxSight Inc. (RXST) PT Lowered to $44 at BTIG
-
RxSight, Inc. (RXST) Tops Q4 EPS by 20c
-
Stifel Reiterates Hold Rating on RxSight Inc. (RXST)
-
RxSight Inc. (RXST) PT Lowered to $35 at Stifel Following 'Somewhat Soft' 4Q24 Preliminary Results
-
Needham Reiterates Buy Rating on RxSight Inc. (RXST)
-
Stifel Downgrades RxSight Inc. (RXST) to Hold
-
Wells Fargo Downgrades RxSight Inc. (RXST) to Equal Weight
-
UBS Starts RxSight Inc. (RXST) at Buy
-
RxSight, Inc. (RXST) Tops Q3 EPS by 25c
-
Jefferies Starts RxSight Inc. (RXST) at Buy
-
Stifel Reiterates Buy Rating on RxSight Inc. (RXST)
-
Stifel Reiterates Buy Rating on RxSight Inc. (RXST)
-
BTIG Reiterates Buy Rating on RxSight Inc. (RXST)
-
Needham Reiterates Buy Rating on RxSight Inc. (RXST)

